1. The FDA plans to introduce new guidance aimed at bringing generic copies of complicated drugs to market more easily. (Forbes)

2. BioMarin sold its priority review voucher to an unidentified buyer for $125 million. Priority review vouchers can shorten the FDA’s drug-review timeline by four months. (Endpoints News)

3. Takeda Pharmaceuticals said it expects results from its Phase-I Zika vaccine trial next year. (Reuters)

4. The United Parcel Service has obtained a manufacturing pharmacy license from Georgia’s Board of Pharmacy. The license would allow the shipping company to transport pharmaceuticals and relabel them. (CNBC)

5. Pfizer has increased the price of its vaccine Prevnar 13 by more than 50% in eight years. (USA Today)